The NeurologyLive® Parkinson disease Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the movement disorder.
Episode 81: Widening the Therapeutic Window in Parkinson Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
FDA Lifts Hold on Phase 2 Trial of Parkinson Agent IKT-148009
Going forward, the company must provide safety and steady-state pharmacokinetic data on the 200 mg dose of IKT-148009, as well as continued measurement of visual acuity and examination of the cornea and lens.
Mesdopetam Fails to Improve ON Time But Shows Anti-Dyskinesia Effects in Parkinson Disease
Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.
Parkinson Disease Agent KM-819 Demonstrates Safe Profile in Phase 2 Study
KM-819, a potent inhibitor of FAF1, a key regulatory protein in cell death pathways, is currently being assessed in a 2-part trial, with results expected to help guide a future 24-month study.
Inconsistency Identified in Techniques Used to Assess Subjective Cognitive Complaints in Parkinson Disease
A systematic review revealed inconsistencies in the literature for assessing subjective cognitive complaints in cognitively normal patients with Parkinson disease.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
Systematic Study Identifies Association Between Incident Parkinson Disease and Antiepileptic Drug Use
Not previously explored, new findings showed links between antiseizure drug prescriptions and incident PD, with trends towards increased risk in those with greater number of prescription issues and multiple AEDs.
Clinical Outlook on ND0612 in Parkinson’s Disease
Ryan Case, PhD, head of clinical medical affairs at NeuroDerm, spoke about the main findings from the phase 3 BouNDless trial of ND0612 for Parkinson disease.
NeuroDerm’s 24-Hour Subcutaneous Levodopa Infusion Meets Primary End Point in Phase 3 BouNDless Study
In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.
CSF Glucocerebrosidase Activity Associated With Risk of Dementia in Parkinson Disease
A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.
Acupuncture Shows Effectiveness for Anxiety in Patients With Parkinson Disease
After 2 months of treatment, findings showed more improvement in anxiety and mental status with acupuncture in patients with Parkinson Disease than those on sham acupuncture.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Timing of Orthostatic Hypotension, Not Symptom Severity, Increases Dementia Risk in Parkinson Disease, Multiple System Atrophy
The increased risk of dementia in patients showing early orthostatic hypotension was independent of the presence of concomitant supine hypertension and other factors associated with cognitive impairment.
Gait Dynamics Highly Associated With Autonomic Dysfunction in De Novo Parkinson Disease
Patients with high dysautonomia scores showed significantly slower walking speed, decreased cadence, and shorter stride but increased time than the lower scored group in backward gait.
Motor Symptoms Predate Prodromal Parkinson Disease by 3 Years, Study Finds
The case-control study identified numerous motor symptoms and signals that are associated with Parkinson disease diagnosis years after they begin to occur.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.
Episode 78: A Virtual Reality Platform for Parkinson Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]
2 Clarke Drive Cranbury, NJ 08512